Appeals Division upholds validity of MYRTOLIN mark


G Pohl-Boskamp recently sought the invalidation of SIA Ingen Pharma’s MYRTOLIN mark, based on its own GELOMYRTOL mark. However, the Appeals Division of the Lithuanian State Patent Bureau found that the marks were dissimilar and there was thus no likelihood of confusion.

Unlock unlimited access to all WTR content